EQRx Aims To Dent Saturated, But Still Expensive, PD-1 Market
Partner CStone Announces Positive NSCLC Results For Sugemalimab
EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.
EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.